EA201390799A1 - Триазолопиридины - Google Patents

Триазолопиридины

Info

Publication number
EA201390799A1
EA201390799A1 EA201390799A EA201390799A EA201390799A1 EA 201390799 A1 EA201390799 A1 EA 201390799A1 EA 201390799 A EA201390799 A EA 201390799A EA 201390799 A EA201390799 A EA 201390799A EA 201390799 A1 EA201390799 A1 EA 201390799A1
Authority
EA
Eurasian Patent Office
Prior art keywords
triazolopryridins
compounds
drugs
formula
well
Prior art date
Application number
EA201390799A
Other languages
English (en)
Other versions
EA022607B1 (ru
Inventor
Александр Флор
Лука Гобби
Катрин Грёбке Цбинден
Маттиас Кёрнер
Йенс-Уве Петерс
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Publication of EA201390799A1 publication Critical patent/EA201390799A1/ru
Publication of EA022607B1 publication Critical patent/EA022607B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

Изобретение относится к триазолопиридиновым соединениям, имеющим формулу (I), где R, R, Rи Rявляются такими, как определено в описании и в формуле изобретения, а также к их физиологически приемлемым солям. Данные соединения ингибируют PDE10A и могут применяться в качестве лекарственных средств.
EA201390799A 2010-12-07 2011-12-05 Триазолопиридины EA022607B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10194014 2010-12-07
PCT/EP2011/071685 WO2012076430A1 (en) 2010-12-07 2011-12-05 Triazolopyridine compounds

Publications (2)

Publication Number Publication Date
EA201390799A1 true EA201390799A1 (ru) 2013-12-30
EA022607B1 EA022607B1 (ru) 2016-01-29

Family

ID=45099086

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201390799A EA022607B1 (ru) 2010-12-07 2011-12-05 Триазолопиридины

Country Status (30)

Country Link
US (1) US8349824B2 (ru)
EP (1) EP2649070B1 (ru)
JP (1) JP5932828B2 (ru)
KR (1) KR20130128426A (ru)
CN (1) CN103237803B (ru)
AR (1) AR084152A1 (ru)
AU (1) AU2011340685A1 (ru)
BR (1) BR112013013912A2 (ru)
CA (1) CA2816829C (ru)
CL (1) CL2013001591A1 (ru)
CO (1) CO6741154A2 (ru)
CR (1) CR20130239A (ru)
CY (1) CY1115863T1 (ru)
DK (1) DK2649070T3 (ru)
EA (1) EA022607B1 (ru)
EC (1) ECSP13012667A (ru)
ES (1) ES2520647T3 (ru)
HR (1) HRP20141200T1 (ru)
IL (1) IL225969A0 (ru)
MA (1) MA35086B1 (ru)
MX (1) MX2013006054A (ru)
PE (1) PE20140226A1 (ru)
PL (1) PL2649070T3 (ru)
PT (1) PT2649070E (ru)
RS (1) RS53677B1 (ru)
SG (1) SG190305A1 (ru)
SI (1) SI2649070T1 (ru)
UA (1) UA109037C2 (ru)
WO (1) WO2012076430A1 (ru)
ZA (1) ZA201303811B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2757883B1 (en) * 2011-09-22 2021-01-13 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
RU2620379C2 (ru) 2012-02-09 2017-05-25 Ф.Хоффманн-Ля Рош Аг СПОСОБ ПОЛУЧЕНИЯ ПРОИЗВОДНЫХ 2-ФЕНИЛ[1,2,4]ТРИАЗОЛО[1,5-а]ПИРИДИНА
BR112015017674A2 (pt) * 2013-01-31 2017-07-11 Hoffmann La Roche compostos rádio marcados
AU2014221799B2 (en) * 2013-02-27 2017-09-28 Mochida Pharmaceutical Co., Ltd. Novel pyrazole derivative
HUE032407T2 (en) 2013-04-30 2017-09-28 Hoffmann La Roche Plasma catalyzed coupling of pyrazolamides
EP3006444B1 (en) * 2013-05-31 2017-09-27 Nissan Chemical Industries, Ltd. Heterocyclic amide compound
WO2015006689A1 (en) 2013-07-12 2015-01-15 University Of South Alabama Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression
EP3176168A4 (en) * 2014-07-30 2018-05-02 Mochida Pharmaceutical Co., Ltd. Pyrazole derivative manufacturing method
WO2016017711A1 (ja) * 2014-07-30 2016-02-04 持田製薬株式会社 ピラゾール誘導体の製造方法
WO2020021024A1 (en) * 2018-07-26 2020-01-30 Phenex Pharmaceuticals Ag Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr)
IL298713A (en) 2020-06-05 2023-02-01 Noema Pharma Ag Use of a phosphodiesterase 10 inhibitor to treat Tourette syndrome
CA3206573A1 (en) * 2021-01-28 2022-08-04 George GARIBALDI Methods for the treatment of childhood-onset fluency disorder

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070032404A1 (en) 2003-07-31 2007-02-08 Bayer Pharmaceuticals Corporation Methods for treating diabetes and related disorders using pde10a inhibitors
TWI501965B (zh) 2008-06-20 2015-10-01 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物

Also Published As

Publication number Publication date
CA2816829C (en) 2018-12-04
AU2011340685A1 (en) 2013-05-23
EA022607B1 (ru) 2016-01-29
UA109037C2 (ru) 2015-07-10
CA2816829A1 (en) 2012-06-14
BR112013013912A2 (pt) 2016-09-13
PT2649070E (pt) 2014-11-21
CY1115863T1 (el) 2017-01-25
ECSP13012667A (es) 2013-08-30
EP2649070B1 (en) 2014-09-17
AR084152A1 (es) 2013-04-24
US8349824B2 (en) 2013-01-08
KR20130128426A (ko) 2013-11-26
JP2013544859A (ja) 2013-12-19
MX2013006054A (es) 2013-06-18
CR20130239A (es) 2013-06-27
SG190305A1 (en) 2013-06-28
PE20140226A1 (es) 2014-03-08
MA35086B1 (fr) 2014-05-02
US20120142665A1 (en) 2012-06-07
JP5932828B2 (ja) 2016-06-08
DK2649070T3 (da) 2014-10-13
ZA201303811B (en) 2014-04-30
HRP20141200T1 (hr) 2015-02-13
CN103237803A (zh) 2013-08-07
ES2520647T3 (es) 2014-11-11
CL2013001591A1 (es) 2013-12-27
WO2012076430A1 (en) 2012-06-14
SI2649070T1 (sl) 2014-12-31
CN103237803B (zh) 2016-04-13
PL2649070T3 (pl) 2015-03-31
CO6741154A2 (es) 2013-08-30
RS53677B1 (en) 2015-04-30
EP2649070A1 (en) 2013-10-16
IL225969A0 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
EA201390799A1 (ru) Триазолопиридины
EA201291282A1 (ru) Азотсодержащие гетероарильные соединения
EA201490599A1 (ru) Соединения триазолопиридина в качестве ингибиторов фосфодиэстеразы pde10a
CY1122853T1 (el) Σταθερα σκευασματα λινακλοτιδης
MA34069B1 (fr) Dérivés de n-(imidazopyrimidin-7-yl)hétéroarylamide et leur utilisation comme inhibiteurs de pde10a)
CY1118680T1 (el) Φαρμακευτικη συνθεση
EA201290880A1 (ru) Новые соединения - ингибиторы фермента
UA114087C2 (xx) Похідні піридину
EA201591166A1 (ru) Ингибиторы аутотаксина
EA201490596A1 (ru) Новые производные дигидрохинолин-2-она
EA201390803A1 (ru) Ингибиторы бромодомена и их применение
EA201401351A1 (ru) Производные бензимидазол-пролина
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
EA201300146A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ МОДУЛЯТОРА c-МЕТ
EA201391274A1 (ru) Аминохинолины в качестве ингибиторов киназ
EA201290183A1 (ru) Бензодиазепиновый ингибитор бромодомена
UA109010C2 (en) MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
UA111717C2 (uk) Склад для перорального введення і ліпофільні солі метилналтрексону
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
EA201490567A1 (ru) Новые бициклические производные дигидрохинолин-2-она
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201201050A1 (ru) Пиразолы в качестве антагонистов crth2
EA201290642A1 (ru) Соединения и способы

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM